Regeneron's COVID-19 antibody drug may be less effective against Omicron_老虎社区_美港股上老虎

Regeneron's COVID-19 antibody drug may be less effective against Omicron

Reuters2021-12-01

Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

116

ToTheMOON
·2021-12-01
Thirty days later than yesterday lol
回复
1
举报
ALi_BaBa
·2021-12-01
Sad
回复
4
举报
AshlynnLee
·2021-12-01
[强]
回复
4
举报
收起
- ALi_BaBa:
  Like
  2021-12-01
  回复
  举报
US_watchlist
·2021-12-01
Please like and comment. Thanks
回复
4
举报
收起
- ToTheMOON:
  Ok
  2021-12-01
  回复
  举报
- BigThumb:
  OkOk! [Smile]
  2021-12-01
  回复
  举报
TradeMore
·2021-12-01
Oh
回复
5
举报
currylow
·2021-12-01
Pls like
回复
3
举报
收起
- MoonMoon:
  Ok
  2021-12-01
  回复
  举报
Jeg
·2021-12-01
Like pls
回复
3
举报
收起
- currylow:
  nice
  2021-12-01
  回复
  举报
calbee_lwh
·2021-12-01
Good
回复
4
举报
MoonMoon
·2021-12-01
Like
回复
4
举报
收起
- calbee_lwh:
  K
  2021-12-01
  回复
  举报
Ahsiang
·2021-12-01
Like pls
回复
3
举报
收起
- Jeg:
  yea
  2021-12-01
  回复
  举报
yigenxiaohai
·2021-12-01
OK
回复
4
举报
PeiLing_Val
·2021-12-01
Like
回复
3
举报
BIGpotato
·2021-12-01
Let’s go
回复
3
举报
收起
- yigenxiaohai:
  OK
  2021-12-01
  回复
  举报
Weeckee
·2021-12-01
Here we go again. Before we can rest an storm a raising. When all these will EnD!!!
回复
3
举报
收起
- Weeckee:
  Pray that we all Survive this calmity
  2021-12-01
  回复
  举报
JL1Apr
·2021-12-01
Regular software upgrade, inspired by Bill Gates.[笑哭]
回复
点赞
举报
Ruixiang
·2021-12-01
Q
回复
4
举报
收起
- Ruixiang:
  Q
  2021-12-01
  回复
  举报
kencarrot
·2021-12-01
Gg
回复
3
举报
WhenLambo69
·2021-12-01
Pls like leh
回复
3
举报
收起
- PeiLing_Val:
  Ok
  2021-12-01
  回复
  举报
- kencarrot:
  ok
  2021-12-01
  回复
  举报
NicOoi
·2021-12-01
[Happy] [Happy] [Happy]
回复
4
举报
Jstan
·2021-12-01
Like pls
回复
3
举报
收起
- NicOoi:
  [Happy]
  2021-12-01
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1101502249?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-01 11:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101502249","market":"us","top_or_hot":-1,"title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","media":"Reuters","content":"<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">网页链接</a>\n\n</div>\n","source":"lsy1601381805984","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","article_id":"1101502249","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","pubTimestamp":1638330314,"sourceInfo":{"source_id":"lsy1601381805984","name":"Reuters"},"weMediaInfo":null,"summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学","REGN":"再生元制药公司","LLY":"礼来","MRNA":"Moderna, Inc."},"translate_title":"雷根龙的新冠肺炎抗体药物对奥米克隆的效果可能较差","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9,"LLY":0.9,"MRNA":0.9,"REGN":0.9},"content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":603962112,"gmtCreate":1638353740423,"gmtModify":1638353741190,"author":{"id":"3576212227172632","authorId":"3576212227172632","name":"ToTheMOON","avatar":"https://static.tigerbbs.com/7769f4b8d26aa1903d8784e79b05b4df","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Thirty days later than yesterday lol&nbsp;","listText":"Thirty days later than yesterday lol&nbsp;","text":"Thirty days later than yesterday lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603962112","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603094057,"gmtCreate":1638335746598,"gmtModify":1638335760303,"author":{"id":"3564105303063302","authorId":"3564105303063302","name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603094057","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603095117,"gmtCreate":1638335653387,"gmtModify":1638335653387,"author":{"id":"4088581130244910","authorId":"4088581130244910","name":"AshlynnLee","avatar":"https://static.tigerbbs.com/8aef70d0693abd07585f544f35472951","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603095117","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6795652,"gmtCreate":1638335753337,"gmtModify":1638335753537,"authorId":3564105303063302,"author":{"id":3564105303063302,"authorId":3564105303063302,"name":"ALi_BaBa","avatar":"https://static.tigerbbs.com/d89722c800111c9c885624fce940701f","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603095117,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"CN"},{"id":603092109,"gmtCreate":1638335558503,"gmtModify":1638335558859,"author":{"id":"3581244873474125","authorId":"3581244873474125","name":"US_watchlist","avatar":"https://static.tigerbbs.com/c45e6bbe1cefb0fecde067a20b3c788f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Please like and comment. Thanks","listText":"Please like and comment. Thanks","text":"Please like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603092109","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6798581,"gmtCreate":1638353748189,"gmtModify":1638353748223,"authorId":3576212227172632,"author":{"id":3576212227172632,"authorId":3576212227172632,"name":"ToTheMOON","avatar":"https://static.tigerbbs.com/7769f4b8d26aa1903d8784e79b05b4df","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603092109,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6795673,"gmtCreate":1638335894375,"gmtModify":1638335894478,"authorId":3581996485604595,"author":{"id":3581996485604595,"authorId":3581996485604595,"name":"BigThumb","avatar":"https://static.tigerbbs.com/d9366427dbceb4a03b5342d31b6c3aaa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603092109,"type":1,"supId":0,"prevId":0,"content":"OkOk! [Smile]","text":"OkOk! [Smile]","html":"OkOk! [Smile]"}],"langContent":"CN"},{"id":603007636,"gmtCreate":1638334718548,"gmtModify":1638334718667,"author":{"id":"4097720712211120","authorId":"4097720712211120","name":"TradeMore","avatar":"https://static.tigerbbs.com/976c10f5e71e9a3b002205015f764d44","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603007636","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603004655,"gmtCreate":1638334656230,"gmtModify":1638334656377,"author":{"id":"3575691555224396","authorId":"3575691555224396","name":"currylow","avatar":"https://static.tigerbbs.com/41cb6bcf4983f1878d086f15607d16b0","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603004655","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6795559,"gmtCreate":1638335012770,"gmtModify":1638335012832,"authorId":3581831647982295,"author":{"id":3581831647982295,"authorId":3581831647982295,"name":"MoonMoon","avatar":"https://static.tigerbbs.com/7abc88bf78bc4fd17d5085b308a74c4d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603004655,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":603005341,"gmtCreate":1638334489821,"gmtModify":1638334489997,"author":{"id":"3575671256883434","authorId":"3575671256883434","name":"Jeg","avatar":"https://static.tigerbbs.com/19188d205b518e713672d6fbc495455b","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603005341","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6795518,"gmtCreate":1638334632108,"gmtModify":1638334632139,"authorId":3575691555224396,"author":{"id":3575691555224396,"authorId":3575691555224396,"name":"currylow","avatar":"https://static.tigerbbs.com/41cb6bcf4983f1878d086f15607d16b0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603005341,"type":1,"supId":0,"prevId":0,"content":"<u>nice</u>","text":"<u>nice</u>","html":"<u>nice</u>"}],"langContent":"CN"},{"id":603008785,"gmtCreate":1638334177320,"gmtModify":1638334177488,"author":{"id":"3579950492873390","authorId":"3579950492873390","name":"calbee_lwh","avatar":"https://static.tigerbbs.com/2c71feed0eaf38825c4f2fc86cd7a84d","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603008785","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609777843,"gmtCreate":1638333415513,"gmtModify":1638333415668,"author":{"id":"3581831647982295","authorId":"3581831647982295","name":"MoonMoon","avatar":"https://static.tigerbbs.com/7abc88bf78bc4fd17d5085b308a74c4d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609777843","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6795458,"gmtCreate":1638334186678,"gmtModify":1638334186773,"authorId":3579950492873390,"author":{"id":3579950492873390,"authorId":3579950492873390,"name":"calbee_lwh","avatar":"https://static.tigerbbs.com/2c71feed0eaf38825c4f2fc86cd7a84d","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609777843,"type":1,"supId":0,"prevId":0,"content":"<u>K</u>","text":"<u>K</u>","html":"<u>K</u>"}],"langContent":"CN"},{"id":609775984,"gmtCreate":1638333135709,"gmtModify":1638333135897,"author":{"id":"3582617881962608","authorId":"3582617881962608","name":"Ahsiang","avatar":"https://static.tigerbbs.com/310f96e7696af85ae33ece774a483d15","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609775984","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6795508,"gmtCreate":1638334511668,"gmtModify":1638334511702,"authorId":3575671256883434,"author":{"id":3575671256883434,"authorId":3575671256883434,"name":"Jeg","avatar":"https://static.tigerbbs.com/19188d205b518e713672d6fbc495455b","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609775984,"type":1,"supId":0,"prevId":0,"content":"<u>yea</u>","text":"<u>yea</u>","html":"<u>yea</u>"}],"langContent":"CN"},{"id":609778138,"gmtCreate":1638332749219,"gmtModify":1638332749417,"author":{"id":"3555200317437246","authorId":"3555200317437246","name":"yigenxiaohai","avatar":"https://static.tigerbbs.com/493bca1476b5cd25c281ec3581efdc01","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609778138","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609778393,"gmtCreate":1638332743862,"gmtModify":1638332744027,"author":{"id":"3576835207750345","authorId":"3576835207750345","name":"PeiLing_Val","avatar":"https://static.tigerbbs.com/2b9811eea8b6682a917378f2b5138a22","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609778393","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609773047,"gmtCreate":1638332530452,"gmtModify":1638332530632,"author":{"id":"3577909078114839","authorId":"3577909078114839","name":"BIGpotato","avatar":"https://static.tigerbbs.com/f332f7e2e29356c4e04cb3e3a9eace8a","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Let’s go","listText":"Let’s go","text":"Let’s go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609773047","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6795254,"gmtCreate":1638332765502,"gmtModify":1638332765587,"authorId":3555200317437246,"author":{"id":3555200317437246,"authorId":3555200317437246,"name":"yigenxiaohai","avatar":"https://static.tigerbbs.com/493bca1476b5cd25c281ec3581efdc01","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609773047,"type":1,"supId":0,"prevId":0,"content":"OK","text":"OK","html":"OK"}],"langContent":"CN"},{"id":609770452,"gmtCreate":1638332363721,"gmtModify":1638332363861,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Here we go again. Before we can rest an storm a raising. When all these will EnD!!!","listText":"Here we go again. Before we can rest an storm a raising. When all these will EnD!!!","text":"Here we go again. Before we can rest an storm a raising. When all these will EnD!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609770452","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6795204,"gmtCreate":1638332423207,"gmtModify":1638332423293,"authorId":3582072953259355,"author":{"id":3582072953259355,"authorId":3582072953259355,"name":"Weeckee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609770452,"type":1,"supId":0,"prevId":0,"content":"Pray that we all Survive this calmity ","text":"Pray that we all Survive this calmity ","html":"Pray that we all Survive this calmity "}],"langContent":"CN"},{"id":609748880,"gmtCreate":1638331686352,"gmtModify":1638335648504,"author":{"id":"4095856449653620","authorId":"4095856449653620","name":"JL1Apr","avatar":"https://static.tigerbbs.com/fa696d7e42a997dc2a7b18b5382eab83","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Regular software upgrade, inspired by Bill Gates.[笑哭]","listText":"Regular software upgrade, inspired by Bill Gates.[笑哭]","text":"Regular software upgrade, inspired by Bill Gates.[笑哭]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609748880","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609757217,"gmtCreate":1638331088047,"gmtModify":1638331088135,"author":{"id":"3573100524668837","authorId":"3573100524668837","name":"Ruixiang","avatar":"https://static.tigerbbs.com/7f71da180ee0c8214a37155cd6d7f87c","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Q","listText":"Q","text":"Q","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609757217","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6794970,"gmtCreate":1638331092389,"gmtModify":1638331092416,"authorId":3573100524668837,"author":{"id":3573100524668837,"authorId":3573100524668837,"name":"Ruixiang","avatar":"https://static.tigerbbs.com/7f71da180ee0c8214a37155cd6d7f87c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609757217,"type":1,"supId":0,"prevId":0,"content":"Q","text":"Q","html":"Q"}],"langContent":"CN"},{"id":609757352,"gmtCreate":1638331038898,"gmtModify":1638331039071,"author":{"id":"3581764784067746","authorId":"3581764784067746","name":"kencarrot","avatar":"https://static.tigerbbs.com/99bb3314847ae532130ee6780cc9cd98","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Gg","listText":"Gg","text":"Gg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609757352","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609754701,"gmtCreate":1638330983420,"gmtModify":1638330983541,"author":{"id":"3581496657430027","authorId":"3581496657430027","name":"WhenLambo69","avatar":"https://static.tigerbbs.com/b7eb252b1bc52ab7567a6f6dbc62f92e","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"Pls like leh","listText":"Pls like leh","text":"Pls like leh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609754701","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6795252,"gmtCreate":1638332758010,"gmtModify":1638332758099,"authorId":3576835207750345,"author":{"id":3576835207750345,"authorId":3576835207750345,"name":"PeiLing_Val","avatar":"https://static.tigerbbs.com/2b9811eea8b6682a917378f2b5138a22","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609754701,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6794960,"gmtCreate":1638331046162,"gmtModify":1638331046203,"authorId":3581764784067746,"author":{"id":3581764784067746,"authorId":3581764784067746,"name":"kencarrot","avatar":"https://static.tigerbbs.com/99bb3314847ae532130ee6780cc9cd98","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609754701,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":609754615,"gmtCreate":1638330921032,"gmtModify":1638330921138,"author":{"id":"3583141251454619","authorId":"3583141251454619","name":"NicOoi","avatar":"https://static.tigerbbs.com/e32399f11520fd0a1d618e2bba8c1342","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[Happy]&nbsp;[Happy]&nbsp;[Happy]&nbsp;","listText":"[Happy]&nbsp;[Happy]&nbsp;[Happy]&nbsp;","text":"[Happy] [Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609754615","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609755526,"gmtCreate":1638330809264,"gmtModify":1638330809432,"author":{"id":"3570885355172302","authorId":"3570885355172302","name":"Jstan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609755526","repostId":1101502249,"repostType":4,"repost":{"id":"1101502249","pubTimestamp":1638330314,"share":"https://www.laohu8.com/m/news/1101502249?lang=&edition=full","pubTime":"2021-12-01 11:45","market":"us","language":"en","title":"Regeneron's COVID-19 antibody drug may be less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1101502249","media":"Reuters","summary":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective ag","content":"<p>Nov 30 (Reuters) - <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.</p>\n<p>Global markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.</p>\n<p>Based on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.</p>\n<p>The company said&nbsp;it was doing further study to quantify the potential impact using the variant's genetic sequence.</p>\n<p>One of the antibodies&nbsp;used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.</p>\n<p>\"<a href=\"https://laohu8.com/S/JE\">Just</a> like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"</p>\n<p><a href=\"https://laohu8.com/S/LLY\">Eli Lilly and</a> Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.</p>\n<p>Regeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.</p>\n<p>Rival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.</p>\n<p>The company is \"working to confirm this in the lab as a matter of urgency\", it added.</p>\n<p>Gilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron</p>\n<p>The U.S. Food &amp; Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's COVID-19 antibody drug may be less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's COVID-19 antibody drug may be less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","GILD":"吉利德科学","MRNA":"Moderna, Inc."},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-covid-19-drug-could-be-less-effective-against-omicron-variant-2021-11-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101502249","content_text":"Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.\nGlobal markets tumbled after comments from Moderna's(MRNA.O)chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.\nBased on its study of Omicron's individual mutations, \"there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity\", Regeneron(REGN.O)said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.\nThe company said it was doing further study to quantify the potential impact using the variant's genetic sequence.\nOne of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.\n\"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals.\"\nEli Lilly and Co(LLY.N), which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.\nRegeneron shares fell about 3% in morning trading, while those of Lillyshed 2.5%.\nRival Vir Biotechnology Inc(VIR.O)said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.\nThe company is \"working to confirm this in the lab as a matter of urgency\", it added.\nGilead Inc(GILD.O)said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron\nThe U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6794938,"gmtCreate":1638330915910,"gmtModify":1638330915945,"authorId":3583141251454619,"author":{"id":3583141251454619,"authorId":3583141251454619,"name":"NicOoi","avatar":"https://static.tigerbbs.com/e32399f11520fd0a1d618e2bba8c1342","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609755526,"type":1,"supId":0,"prevId":0,"content":"[Happy]","text":"[Happy]","html":"[Happy]"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":116,"commentSize":22,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}